Texas Prescription Drug
Misuse Prevention Summit

Nearly 200 individuals representing a multitude of sectors converged in Austin at a Texas Prescription Drug Misuse Prevention Summit to offer their input on the development of a statewide strategic plan to address this growing problem. The sectors represented included: healthcare professionals, business, youth, parents, schools and universities, religious organizations, law enforcement officials, local communities, volunteer organizations, veterans, the elderly and the LGBT community. A copy of the strategic plan will be posted in March.

For a copy of the agenda, presentations and handouts from the summit, please click here.

The summit was held to address the growing prescription drug misuse epidemic in Texas. Rates of prescription drug misuse in Texas are alarmingly high. One out of five Texas high school students have taken prescription drugs without a doctor’s prescription at least once in their lifetime.1  In 2015, Texas had the second highest total healthcare costs from opioid abuse in the nation ($1.96 billion)2 and Texas is home to four of the top 25 cities in the U.S. for opioid abuse.3 Meanwhile, only one in three prescribers is using the statewide Prescription Drug Monitoring Program (PDMP)4 leading to a massive loss of data.  There is substantial need for increased infrastructure and prevention measures in Texas, especially related to the emergence of prescription drug misuse. 

Over the next few months, the Texas Health and Human Services Commission (HHSC) will follow up the statewide summit with regional prescription drug misuse prevention town hall meetings. If you are interested in attending, please click on the link below.

  • 1 Texas Youth Risk Behavior Surveillance System (YRBS) (2013).
  • 2 Matrix Global Advisors, LLC, disseminated by The Partnership for Drug-Free Kids.
  • 3 Castlight Health, Inc. listed. (Texarkana at 10th, Amarillo at 13th, Odessa at 15th, and Longview at 17th) (2015).
  • 4 U.S. Drug Enforcement Administration (DEA) (2016).